The scene is familiar in biotech: a small conference room, a slide deck calibrated to the minute, a founder explaining a molecule’s promise to people trained to doubt. The science is intricate, the stakes are human, and the room’s energy still hinges on something that is hard to name, an unspoken question of credibility.
Leen Kawas has lived inside that room from multiple angles: scientist, chief executive, board director, investor. She is CEO of EIT Pharma and Managing General Partner at Propel Bio Partners, a biotech-focused venture firm built to pair capital with hands-on support. She serves on the board of Inherent Biosciences and has described her work across drug discovery, clinical strategy, regulatory pathways, commercialization, and financing. Her earlier chapter included taking Athira Pharma public in 2020, with bios noting more than $400 million raised around that phase of growth.
When Kawas talks about women in biotech, the point is not inspiration. It is architecture. She treats the barriers as real, then asks what systems would make them less powerful.
The first move: make visibility a craft
Kawas’s career hints at a lesson that younger founders often miss: visibility is not vanity, it is infrastructure. In a profile from Life Science Leader, she described learning the business of biotech through networking, tracking the connections she built as a way to push herself past discomfort.
Her call to action begins here because the biotech industry runs on trust, and trust runs on repeated contact. A woman building a company cannot wait to be discovered. She has to practice being findable: showing up in rooms where decisions get made, joining networks with real deal flow, offering expertise in ways that create invitations back.
This is not a plea to “network more.” It is a reminder that relationship-building has compounding returns, and it can be approached with the same discipline as a clinical plan.
The second move: replace mentorship fantasies with sponsorship reality
Leen Kawas emphasizes mentorship, yet she draws a line between advice and advocacy. In coverage connected to her leadership perspective, she points toward mentors and advocates who will actively push a woman’s growth, especially when informal access is uneven.
In biotech, sponsorship is the hidden accelerant. It is the senior leader who introduces you to the investor who writes the first check. It is the board member who helps you frame a risk as a reasonable bet. It is the executive who says your name when a leadership role opens.
Kawas’s call to action is practical: build relationships with people willing to attach their credibility to yours. If that sounds transactional, it is. Biotech can be unforgiving, and women do not benefit from pretending the system is purely meritocratic.
The third move: treat caregiving as leadership training, then demand systems that agree
Kawas has argued that caregiving develops executive muscles: crisis management, emotional intelligence, collaborative problem-solving. She pushes companies to stop treating motherhood and caregiving as a professional liability and to design advancement paths that do not rely on an “always available” model.
This is a call to action aimed at women and at the organizations that want their talent to stay. The industry cannot keep saying it needs innovative thinking while it filters out leaders whose lives include responsibility outside work.
Kawas’s own positioning makes that argument harder to dismiss. Her biography across industry sources frames her as building a venture platform while raising young children, which turns the topic from theory into lived operational reality.
The message is not that mothers are heroic. The message is that leadership is more complex than hours logged, and companies that fail to update their assumptions will lose capable people.
The fourth move: change how capital decides
In biotech, the gatekeeping often sits with investment committees, pattern recognition, and assumptions about who looks “fundable.” Leen Kawas has spoken about bias in investment decision-making and the importance of naming it, so teams can challenge their default preferences.
Her call to action for women founders is to learn the capital system well enough to navigate it without being shaped by it. Know what signals investors are trained to seek. Learn to translate the science into risk language. Build a financing strategy that matches the company’s milestones, then hold your boundaries when outside pressure tries to pull the company toward short-term optics.
Her call to action for funds and boards is sharper: stop confusing familiarity with quality. Propel Bio Partners describes its model as extending beyond financial investment into operational support, with an emphasis on patient-centric progress and support for diverse leadership teams. That framing is a direct challenge to the idea that the market alone will fix representation.
A closing standard that is easy to remember, hard to live
Kawas has a habit of tying ambition to patient impact, a through-line in how she is described across her operating and investing roles, and reinforced by the vantage point she brings as a board director at Inherent Biosciences. Her call to action for women in biotech flows from that: make your work so real that it cannot be reduced to optics, then refuse to shrink your leadership to match outdated expectations.
The industry loves to celebrate the rare woman who breaks through. Kawas’s push is toward something less flattering and more important: building conditions where “rare” stops being the adjective.